Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
9th April 2021

Congratulations Greg and team on the successful IPO of Reneo Pharma on Nasdaq (ticker: RPHM)

23rd March 2021

Delighted to share Reneo Pharmaceuticals has appointed Vineet R. Jindal as Chief Financial Officer

15th March 2021

Pleased to announce Reneo Pharmaceuticals has appointed Eric Dube, Ph.D. to its Board of Directors

11th March 2021

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

10th March 2021

Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate

9th March 2021

Exicure announces appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to its Board of Directors

9th March 2021

We are delighted that Q32 Bio has appointed Dr. Jason Campagna as Chief Medical Officer

5th March 2021

Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors

17th February 2021

Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer

10th February 2021

Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement

8th February 2021

Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

3rd February 2021

Abingworth raises $465m for new life sciences fund Abingworth Bioventures 8

21st January 2021

Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer

19th January 2021

We are pleased to announce Vera Therapeutics has launched with an $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

7th January 2021

Congratulations Gary Glick, CEO and the Scorpion Therapeutics team on an oversubscribed $162 million Series B financing